Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

The abstract describes 690 patients taking part.

By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Proportions of patients with optimal/sufficient (≥30 ng/ml), insufficient (21-29 ng/ml), deficient (10-20 ng/ml) and severely deficient (<10 ng/ml) 25(OH)D levels were determined.

Data are presented for patients with paired baseline and week 48 25(OH)D data (rilpivirine, n=292; efavirenz, n=290).

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Topics PubMed links to this paper include Alkynes, Anti-HIV Agents, Benzoxazines, Cyclopropanes, HIV Infections, HIV-1 and Nitriles.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 690 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Antiviral therapy), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.